These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16158247)

  • 1. SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
    Zheng R; Yano S; Matsumori Y; Nakataki E; Muguruma H; Yoshizumi M; Sone S
    Clin Exp Metastasis; 2005; 22(3):195-204. PubMed ID: 16158247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration.
    Ali N; Yoshizumi M; Fujita Y; Izawa Y; Kanematsu Y; Ishizawa K; Tsuchiya K; Yano S; Sone S; Tamaki T
    J Pharmacol Sci; 2005 Jun; 98(2):130-41. PubMed ID: 15937404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association.
    Ali N; Yoshizumi M; Yano S; Sone S; Ohnishi H; Ishizawa K; Kanematsu Y; Tsuchiya K; Tamaki T
    J Pharmacol Sci; 2006 Sep; 102(1):112-20. PubMed ID: 16974068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
    Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
    Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
    Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
    Nguyen QD; Rodrigues S; Rodrigue CM; Rivat C; Grijelmo C; Bruyneel E; Emami S; Attoub S; Gespach C
    Mol Cancer Ther; 2006 Aug; 5(8):2070-7. PubMed ID: 16928828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
    Zheng R; Qin X; Li W; Kang J
    Zhongguo Fei Ai Za Zhi; 2011 Jan; 14(1):13-7. PubMed ID: 21219825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
    Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
    Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
    Rothschild SI; Gautschi O; Batliner J; Gugger M; Fey MF; Tschan MP
    Lung Cancer; 2017 May; 107():73-83. PubMed ID: 27372519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
    Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
    Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H; Hu Z; Huiwen M; Zhijun L; Jiaojie Z; Xiaoyi Y; Xiujun C
    Biochem Biophys Res Commun; 2015 Aug; 464(2):422-7. PubMed ID: 26102035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of Src on proliferation and invasion of lung cancer cells].
    Zheng R; Qin X; Li W; Kang J
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):311-6. PubMed ID: 21496428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
    Hingorani P; Zhang W; Gorlick R; Kolb EA
    Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
    Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
    Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
    Summy JM; Trevino JG; Lesslie DP; Baker CH; Shakespeare WC; Wang Y; Sundaramoorthi R; Metcalf CA; Keats JA; Sawyer TK; Gallick GE
    Mol Cancer Ther; 2005 Dec; 4(12):1900-11. PubMed ID: 16373705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.